Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Arm Phase II Study Assessing Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-multiple cN2 or IIIB)

NCT00271323 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00271323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00271323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Arm Phase II Study Assessing Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-multiple cN2 or IIIB)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2005
Completion date
February 28, 2007
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma